Last reviewed · How we verify

Abemaciclib + Fulvestrant — Competitive Intelligence Brief

Abemaciclib + Fulvestrant (Abemaciclib + Fulvestrant) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CDK4/6 inhibitor + estrogen receptor antagonist. Area: Oncology.

marketed CDK4/6 inhibitor + estrogen receptor antagonist CDK4/6 and estrogen receptor (ER) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Abemaciclib + Fulvestrant (Abemaciclib + Fulvestrant) — Prof. Wolfgang Janni. Abemaciclib inhibits CDK4/6 to block cell cycle progression, while fulvestrant is an estrogen receptor antagonist that degrades the ER protein, together blocking hormone-driven breast cancer growth.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Abemaciclib + Fulvestrant TARGET Abemaciclib + Fulvestrant Prof. Wolfgang Janni marketed CDK4/6 inhibitor + estrogen receptor antagonist CDK4/6 and estrogen receptor (ER)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CDK4/6 inhibitor + estrogen receptor antagonist class)

  1. Prof. Wolfgang Janni · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Abemaciclib + Fulvestrant — Competitive Intelligence Brief. https://druglandscape.com/ci/abemaciclib-fulvestrant. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: